Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

These side effects can be intolerable. In clinical trials, the participant withdrawal rate due to adverse events in the GLP-1 RA group was 1.6%-6% compared with less than 0.1% in the placebo group ...

The researchers found that the incidence of VTE was 11.0 versus 12.9 events per 1,000 patient-years in the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18 percent lower risk for VTE ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects ...

This yielded 25,838 with SLE and T2D, of whom 910 initiated a GLP-1 RA and 1004 started a DPP4i, and 12,387 with lupus nephritis and T2D, including 267 on a GLP-1 RA and 324 on a DPP4i.

Before adjustment, for example, the GLP-1 RA group tended to be older (median 74 vs 67) and had more comorbidities like CKD (46.5% vs 33.2%) and coronary artery disease (70.1% vs 58.1%).

Among 220,822 patients with T2D who were included in the study, there were 47,526 GLP-1 RA users, 32,203 thiazolidinedione users, 30,682 combination therapy users, and a matched nonuser control group.

Within the subclass of GLP-1 RAs, semaglutide increased the most, from 0.2 to 4.4% from 2018 to 2023. Within one year, tirzepatide, which was approved in 2022, reached 1.3%.

The analysis included 18,016 kidney transplant recipients with diabetes (2013 through 2020) covered by Medicare, of whom 10.9% had at least one GLP-1 RA prescription filled posttransplant.

Meeting Coverage > ADA Investigational GLP-1 RA Cuts Heart, Renal Risk in Vulnerable Diabetes Patients — Exendin-4-based drug succeeded in cardiovascular outcomes trial ...

BELLEVUE, Wash., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has ...

GLP-1 RA medications safe and effective for treating obesity in adults with mental illness Comprehensive review of available evidence finds GLP-1RAs lead to significant weight loss and ...